BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robak P, Jarych D, Mikulski D, Dróżdż I, Węgłowska E, Kotkowska A, Misiewicz M, Smolewski P, Stawiski K, Fendler W, Szemraj J, Robak T. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Cancers (Basel) 2021;13:951. [PMID: 33668794 DOI: 10.3390/cancers13050951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Puła A, Robak P, Mikulski D, Robak T. The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications. Int J Mol Sci 2021;22:12070. [PMID: 34769503 DOI: 10.3390/ijms222112070] [Reference Citation Analysis]
2 Robak P, Szemraj J, Mikulski D, Drozdz I, Juszczak K, Jarych D, Misiewicz M, Kościelny K, Fendler W, Robak T. Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. J Clin Med 2021;10:5028. [PMID: 34768548 DOI: 10.3390/jcm10215028] [Reference Citation Analysis]
3 Bębnowska D, Hrynkiewicz R, Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, Smarz-Widelska I, Góźdź S, Roliński J, Niedźwiedzka-Rystwej P. Immunological Prognostic Factors in Multiple Myeloma. Int J Mol Sci 2021;22:3587. [PMID: 33808304 DOI: 10.3390/ijms22073587] [Reference Citation Analysis]